Epsigam fusion protein
AssigneeTunitas Therapeutics, Inc.
InventorsNolan Sigal, Gizette Sperinde
Life of this patent
Estimating the term…
Abstract
Epsi-gam provides a novel fusion protein with the ability to cross-link either of the FcεRI or FcεRII cell surface receptors with an FcγRIIb cell surface receptor in order to block IgE-mediated biological responses.
Claims15
A method for manufacturing a pharmaceutical composition comprising a fusion protein comprising the sequence of SEQ ID NO:2, said method comprising
- synthesizing said fusion protein;
- and
- isolating said fusion protein, wherein said fusion protein aggregates at a rate of 6% or less.
A method for providing a first therapeutic agent to a subject, wherein said subject has had an allergic reaction to said first therapeutic agent in the past or said first therapeutic agent is expected to produce an allergic reaction in said subject, said method comprising
- providing to said subject a fusion protein comprising of the sequence of SEQ ID NO:2 thus desensitizing said subject;
- and
- providing to said subject said first therapeutic agent.
Dependencies are inferred from the claim text.